Earningsreport

Q1/2024 3/31/2024 EPS -0.560 ZacksConsensus -0.610 ActVsEst 0.050 - Beat

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com